H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced nonsquamous non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9094: First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.
Advertisement